Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Alcon Inc (ALC)

Alcon Inc (ALC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,172,360
  • Shares Outstanding, K 493,244
  • Annual Sales, $ 9,455 M
  • Annual Income, $ 974,000 K
  • EBIT $ 1,226 M
  • EBITDA $ 2,452 M
  • 60-Month Beta 0.99
  • Price/Sales 4.46
  • Price/Cash Flow 16.30
  • Price/Book 1.97

Options Overview Details

View History
  • Implied Volatility 20.68% ( +0.52%)
  • Historical Volatility 20.84%
  • IV Percentile 37%
  • IV Rank 33.00%
  • IV High 33.65% on 08/05/24
  • IV Low 14.30% on 03/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 681
  • Put/Call OI Ratio 1.06
  • Today's Open Interest 4,646
  • Open Int (30-Day) 5,782

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.73
  • Number of Estimates 5
  • High Estimate 0.79
  • Low Estimate 0.69
  • Prior Year 0.70
  • Growth Rate Est. (year over year) +4.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.92 +1.85%
on 11/15/24
95.14 -10.16%
on 10/28/24
-8.86 (-9.40%)
since 10/21/24
3-Month
83.92 +1.85%
on 11/15/24
101.10 -15.45%
on 09/12/24
-9.14 (-9.66%)
since 08/21/24
52-Week
71.46 +19.62%
on 12/08/23
101.10 -15.45%
on 09/12/24
+13.14 (+18.16%)
since 11/21/23

Most Recent Stories

More News
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours

Alcon, Inc. ALC delivered core earnings per share (EPS) of 81 cents for the third quarter of 2024, up 22.7% from the year-ago quarter’s figure (up 25% at the constant exchange rate or CER). The figure...

DGX : 163.98 (+1.65%)
BSX : 91.43 (+1.40%)
RMD : 242.20 (+0.27%)
ALC : 85.36 (-0.16%)
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value

The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.

ALC : 85.36 (-0.16%)
BLCO : 19.66 (+1.44%)
BHC : 8.15 (-0.49%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END

OKYO : 1.0700 (unch)
ALC : 85.36 (-0.16%)
BLCO : 19.66 (+1.44%)
JNJ : 155.63 (+1.65%)
RHHBY : 35.5000 (+1.05%)
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030

/PRNewswire/ -- The Global Dry Eye Syndrome market has been growing substantially in the past years and is expected to continue through 2030. Dry Eye Syndrome...

OKYO : 1.0700 (unch)
ALC : 85.36 (-0.16%)
BLCO : 19.66 (+1.44%)
JNJ : 155.63 (+1.65%)
RHHBY : 35.5000 (+1.05%)
Stock Index Futures Plunge on Pressure from Rising Bond Yields, China Data Disappoints

September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
NVDA : 147.10 (+0.83%)
X : 40.67 (+5.97%)
MNDY : 276.70 (+6.36%)
TSLA : 341.45 (-0.17%)
KEY : 19.34 (+1.68%)
CMA : 69.08 (+1.77%)
HD : 409.57 (+2.39%)
SU : 41.15 (+0.78%)
ALC : 85.36 (-0.16%)
A : 131.89 (+2.58%)
New Head-to-Head Data Show Clareon Monofocal IOLs and TECNIS Eyhance Monofocal IOLs Provide Similar Range of Vision

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced results from a new study presented at the American Society of Cataract and Refractive Surgery...

ALC : 85.36 (-0.16%)
Alcon Announces Results of 2023 Annual General Meeting

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed resolutions at its 2023 Annual General Meeting (AGM)....

ALC : 85.36 (-0.16%)
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy

The Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product...

MMED.NE : 14.9000 (+9.48%)
MNMD : 7.12 (-5.32%)
INCY : 70.18 (-1.22%)
SGEN : 228.74 (-0.07%)
PFE : 25.02 (+0.32%)
FBRX : 14.83 (+9.45%)
JAZZ : 124.85 (+4.70%)
ALC : 85.36 (-0.16%)
Alcon Announces Largest-Ever Scientific Presence at ASCRS 2023 and Expands Image-Guided Connectivity

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will once again have the largest surgical ophthalmic presence at the American Society of Cataract and Refractive...

ALC : 85.36 (-0.16%)
Alcon Publishes Agenda for 2023 Annual General Meeting

Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 5, 2023.

ALC : 85.36 (-0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma...

See More

Key Turning Points

3rd Resistance Point 86.44
2nd Resistance Point 86.05
1st Resistance Point 85.78
Last Price 85.36
1st Support Level 85.11
2nd Support Level 84.72
3rd Support Level 84.45

See More

52-Week High 101.10
Fibonacci 61.8% 89.78
Fibonacci 50% 86.28
Last Price 85.36
Fibonacci 38.2% 82.78
52-Week Low 71.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar